BioMarin heads to FDA with hemophilia A gene therapy; Covid-focused biotech signs a small SPAC deal
BioMarin’s gene therapy is getting a shot at the FDA as the agency accepted the BLA, the biotech said Wednesday night …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
